No products in the cart.
Rabbit Polyclonal Phospho-ErbB-4 (Y1284) antibody (STJ91084)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, IF, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000;
Recommended protocols: check protocols
Click or hover above images to see image description for ErbB-4 (phospho Tyr1284) Polyclonal Antibody.
Check alternative names for the antibodyExpand
ERBB4 antibody, HER4 antibody,|4ICD antibody|ALS19 antibody|Avian erythroblastic leukemia viral oncogene homolog 4 antibody|Avian erythroblastic leukemia viral v erb b2 oncogene homolog 4 antibody|E4ICD antibody|EC 126.96.36.199 antibody|Erbb4 antibody|ERBB4 intracellular domain antibody|ERBB4_HUMAN antibody|HER 4 antibody|HER4 antibody|human epidermal growth factor receptor 4 antibody|Mer4 antibody|MGC138404 antibody|Oncogene ERBB4 antibody|p180erbB4 antibody|Proto-oncogene-like protein c-ErbB-4 antibody|Receptor protein tyrosine kinase erbB 4 precursor antibody|Receptor tyrosine protein kinase erbB 4 antibody|s80HER4 antibody|Tyrosine kinase type cell surface receptor HER4 antibody|Tyrosine kinase-type cell surface receptor HER4 antibody|v erb a avian erythroblastic leukemia viral oncogene homolog like 4 antibody|v erb a erythroblastic leukemia viral oncogene homolog 4 antibody|v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) antibody|V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 4 antibody|Verba avian erythroblastic leukemia viral oncogene homolog like 4 antibody|Verba erythroblastic leukemia viral oncogene homolog 4 antibody|VERBB2 antibody|Anti-ErbB 4 antibody [HFR-1] (ab19391)
SCBT cat No: sc-71071|sc-71070|sc-81456|sc-514327|sc-283|sc-8050|sc-515142|sc-31150|sc-514462|sc-53280|sc-31149|sc-293468|sc-30054|
ErbB-4 (phospho Tyr1284) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-ErbB-4 (Y1284) Polyclonal Antibody detects endogenous levels of ErbB-4 protein only when phosphorylated at Y1284.
Synthesized phospho-peptide derived from ErbB-4 (phospho Tyr1284) at AA range 1220-1300
WB, IHC, IF, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000;
|Molecular weight|| |
ErbB-4 (phospho Tyr1284) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
ErbB-4 (phospho Tyr1284) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Receptor tyrosine-protein kinase erbB-4 antibody, Proto-oncogene-like protein c-ErbB-4 antibody, Tyrosine kinase-type cell surface receptor HER4 antibody, p180erbB4 antibody
|Protein names|| |
Receptor tyrosine-protein kinase erbB-4 , Proto-oncogene-like protein c-ErbB-4 , Tyrosine kinase-type cell surface receptor HER4 , p180erbB4
|Protein function|| |
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. / ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. / Binding of a cognate ligand leads to dimerization and activation by autophosphorylation on tyrosine residues. In vitro kinase activity is increased by Mg2+. Inhibited by PD153035, lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS.
|Protein tissue specificity|| |
Expressed at highest levels in brain, heart, kidney, in addition to skeletal muscle, parathyroid, cerebellum, pituitary, spleen, testis and breast. Lower levels in thymus, lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B is expressed in the heart.
|Involvement in disease|| |
Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. / Contains 1 protein kinase domain.
|Protein post-translational modifications|| |
Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. Proteolytic processing in response to ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation results in the production of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 kDa fragments (m80HER4), which are further processed by a presenilin-dependent gamma-secretase to release a cytoplasmic intracellular domain (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 are more readily degraded by the proteasome than fragments of isoform JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not processed by ADAM17, precluding further processing by gamma-secretase. / Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Ligands trigger phosphorylation at specific tyrosine residues, thereby creating binding sites for scaffold proteins and effectors. Constitutively phosphorylated at a basal level when overexpressed in heterologous systems; ligand binding leads to increased phosphorylation. Phosphorylation at Tyr-1035 is important for interaction with STAT1. Phosphorylation at Tyr-1056 is important for interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively phosphorylated on tyrosine residues in a ligand-independent manner. E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. / Ubiquitinated. During mitosis, the ERBB4 intracellular domain is ubiquitinated by the APC/C complex and targeted to proteasomal degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is ubiquitinated, and this involves NEDD4.
|Protein cellular localization|| |
Cell membrane / Single-pass type I membrane protein / Nucleus / Mitochondrion
AntibodyPlus can customize ErbB-4 (phospho Tyr1284) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: